Pauli M Turunen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3893892/publications.pdf

Version: 2024-02-01

1478505 1588992 9 121 8 6 citations h-index g-index papers 9 9 9 201 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Calpain Activity Is Essential for ATP-Driven Unconventional Vesicle-Mediated Protein Secretion and Inflammasome Activation in Human Macrophages. Journal of Immunology, 2016, 197, 3315-3325.	0.8	49
2	Regulation of radial glial process growth by glutamate via mGluR5/TRPC3 and neuregulin/ErbB4. Glia, 2018, 66, 94-107.	4.9	17
3	Transient Receptor Potential Channels and Their Role in Modulating Radial Glial–Neuronal Interaction: A Signaling Pathway Involving mGluR5. Stem Cells and Development, 2015, 24, 701-713.	2.1	15
4	Cellular Signaling Mechanisms of Hypocretin/Orexin. Frontiers of Neurology and Neuroscience, 2021, 45, 91-102.	2.8	15
5	Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26. European Journal of Pharmacology, 2018, 837, 137-144.	3.5	11
6	Endocannabinoid Signaling in Embryonic Neuronal Motility and Cell–Cell Contact – Role of mGluR5 and TRPC3 Channels. Neuroscience, 2018, 375, 135-148.	2.3	7
7	Stapled truncated orexin peptides as orexin receptor agonists. Peptides, 2018, 102, 54-60.	2.4	6
8	Neurotransmitters and Endothelins Acting on Radial Glial G-Protein-Coupled Receptors Are, Through Proteolytic NRG/ErbB4 Activation, Able to Modify the Migratory Behavior of Neocortical Cells and Mediate Bipolar-to-Multipolar Transition. Stem Cells and Development, 2020, 29, 1160-1177.	2.1	1
9	Orexin/hypocretin receptor agonists: Pharmacological characterization of Nag 26 and discovery of novel agonist/potentiator structures based on the azulene scaffold. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR6-2.	0.0	O